NCT00053989View on ClinicalTrials.gov

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 29, 2002

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesFanconi AnemiaAplastic Anemia
Interventions
BIOLOGICAL

anti-thymocyte globulin

iv

BIOLOGICAL

graft-versus-tumor induction therapy

iv

BIOLOGICAL

sargramostim

iv

BIOLOGICAL

therapeutic allogeneic lymphocytes

iv

DRUG

cyclophosphamide

injection

DRUG

fludarabine phosphate

iv

DRUG

methylprednisolone

oral

DRUG

mycophenolate mofetil

oral

DRUG

tacrolimus

oral

PROCEDURE

allogeneic bone marrow transplantation

iv

PROCEDURE

peripheral blood stem cell transplantation

iv

PROCEDURE

umbilical cord blood transplantation

iv

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00053989 - NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders | Biotech Hunter | Biotech Hunter